Clinical Trial Update: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) [Phase 1]

View source ↗

Summary

Phase 1b safety study of Xevinapant with weekly cisplatin and radiotherapy in unresected locally advanced head and neck squamous cell carcinoma has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Xevinapant (Xevinapant)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Head and Neck Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-09-29